deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT02662712

A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Subjects (Part I), and After Multiple Dose Regimens in Subjects With Chronic Hepatitis B (Part II)

Sponsor: Janssen Sciences Ireland UC

Conditions Healthy Hepatitis, Chronic
Interventions JNJ-56136379 Placebo
Updated 14 times since 2017 Last updated: Jan 31, 2025 Started: Dec 17, 2015 Primary completion: Jun 29, 2018 Completion: Jun 29, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02662712, this PHASE1 trial focuses on Healthy and Hepatitis, Chronic and remains completed. Sponsored by Janssen Sciences Ireland UC, it has been updated 14 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Mar 2017 · 59 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Aug 2019 · 12 months · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 9 earlier versions

  1. Aug 2019 — Jan 2021 [monthly]

    Completed PHASE1

  2. Aug 2018 — Aug 2019 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  3. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  4. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  5. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  6. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  7. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE1

  8. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

  9. Jan 2017 — Mar 2017 [monthly]

    Recruiting PHASE1

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Sciences Ireland UC
Data source: Janssen Sciences Ireland UC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Brussels, Belgium , Bucharest, Romania , Chisinau, Moldova , Clichy, France , Edegem, Belgium , Essen, Germany , Hanover, Germany , Kaohsiung City, Taiwan , Keelung, Taiwan and 17 more locations